

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Southern Home Medical, Inc.

A Wyoming Corporation

6417 18th Ave
Brooklyn, NY 11214
(718) 675-3880

liyong168inus@gmail.com

Quarterly Report

For the Period Ending: March 31, 2022 (the "Reporting Period")

As of March 31, 2022, the number of shares outstanding of our Common Stock was: 3,986,704,512

As of December 31, 2021, the number of shares outstanding of our Common Stock was: 3,986,704,512

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

Southern Home Medical, Inc. (Since 3/20/2012)

Southern Home Medical Equipment, Inc. (Since incorporation, 1/13/2005)

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

The State of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

1/13/2005 State of Nevada - Southern Home Medical Equipment, Inc. (Incorporated)
3/20/2012 State of Nevada – Change name to Southern Home Medical, Inc.
2/2/2016 State of Wyoming – Articles of Domestication filed (active).

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

Issuer's principal executive office is located at 122 12th Street, Brooklyn, New York 11214.

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

2) Security Information

Trading symbol:	<u>SHOM</u>
Exact title and class of securities outstanding:	<u>Common Stock</u>
CUSIP:	<u>84305M206</u>
Par or stated value:	<u>\$.001</u>
Total shares authorized:	<u>5,000,000,000</u> as of date: <u>03/31/2022</u>
Total shares outstanding:	<u>3,986,704,512</u> as of date: <u>03/31/2022</u>
Number of shares in the Public Float ² :	<u>1,184,749,512</u> as of date: <u>03/31/2022</u>
Total number of shareholders of record:	<u>1,949</u> as of date: <u>03/31/2022</u>

Additional class of securities (if any):

Trading symbol:	<u>N/A</u>
Exact title and class of securities outstanding:	<u>Series A Preferred Stock</u>
CUSIP:	<u>N/A</u>
Par or stated value:	<u>\$.001</u>
Total shares authorized:	<u>25,000,000</u> as of date: <u>03/31/2022</u>
Total shares outstanding:	<u>10,000,000</u> as of date: <u>03/31/2022</u>

Trading symbol:	<u>N/A</u>
Exact title and class of securities outstanding:	<u>Series C Preferred Stock</u>
CUSIP:	<u>N/A</u>
Par or stated value:	<u>\$.001</u>
Total shares authorized:	<u>25,000,000</u> as of date: <u>03/31/2022</u>
Total shares outstanding:	<u>10,516,250</u> as of date: <u>03/31/2022</u>

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

Transfer Agent

Name: Transfer Online, Inc.
Phone: 503.227.6874
Email: info@transferonline.com
Address: 512 SE Salmon St., Portland, OR 97214

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

3) Issuance History

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☒

Number of Shares outstanding as of <u>12/31/2020</u>	<u>Opening Balance:</u> Common: <u>3,986,704,512</u> Series A Preferred: <u>10,000,000</u> Series C Preferred: <u>10,516,250</u>		*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
Shares Outstanding on <u>03/31/2022</u> :	<u>Ending Balance:</u> Common: <u>3,986,704,512</u> Series A Preferred: <u>10,000,000</u> Series C Preferred: <u>10,516,250</u>								

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe any issuance of promissory notes, convertible notes or convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: VINCENT XIAO, CPA
VX Accounting & Tax Inc
Title: Outside Accounting Firm
Relationship to Issuer: Outside Accounting Firm

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

SOUTHERN HOME MEDICAL INC**Balance Sheet****As of March 31, 2022**

(Unaudited)

	<u>Mar 31, 22</u>
ASSETS	
Current Assets	
Checking/Savings	
TD Bank Checking	\$ 3,000.00
Total Checking/Savings	<u>\$ 3,000.00</u>
Other Current Assets	
Prepaid Expenses	
OTC Service Fees	\$ 4,250.02
Total Prepaid Expenses	<u>\$ 4,250.02</u>
Total Other Current Assets	<u>\$ 4,250.02</u>
Total Current Assets	<u>\$ 7,250.02</u>
Fixed Assets	
Property and Equipment	
Accumulated Depreciation	\$ (1,200.00)
Property and Equipment - Other	\$ 1,200.00
Total Property and Equipment	<u>\$ -</u>
Total Fixed Assets	<u>\$ -</u>
Other Assets	
Security Deposits Asset	
Security Deposits	\$ 1,500.00
Total Security Deposits Asset	<u>\$ 1,500.00</u>
Total Other Assets	<u>\$ 1,500.00</u>
TOTAL ASSETS	<u><u>\$ 8,750.02</u></u>
LIABILITIES & EQUITY	
Liabilities	
Current Liabilities	
Other Current Liabilities	
Due to Officers	\$ 153,653.06
Loans & Exchanges	\$ 68,567.85
Total Other Current Liabilities	<u>\$ 222,220.91</u>
Total Current Liabilities	<u>\$ 222,220.91</u>
Total Liabilities	<u>\$ 222,220.91</u>
Equity	
Common Stock	\$ 102,907.00
Preferred A	\$ 19,827.00
Preferred C	\$ 18,006.00
Retained Earnings	\$ (347,919.20)
Net Income	\$ (6,291.69)
Total Equity	<u>\$ (213,470.89)</u>
TOTAL LIABILITIES & EQUITY	<u><u>\$ 8,750.02</u></u>

The accompanying notes are an integral part of these financial statements.

SOUTHERN HOME MEDICAL INC

Statement of Income **January through March 2022** **(Unaudited)**

	<u>Jan - Mar 22</u>
Ordinary Income/Expense	
Expense	
Bank Service Charges	30.00
Legal & Professional Fees	
Legal	4,136.70
OTC Service Fees	2,124.99
Total Legal & Professional Fees	<u>6,261.69</u>
Total Expense	<u>6,291.69</u>
Net Ordinary Income	<u>(6,291.69)</u>
Net Income	<u><u>(6,291.69)</u></u>

The accompanying notes are an integral part of these financial statements.

SOUTHERN HOME MEDICAL INC**Statement of Cash Flows**

January through March 2022

(Unaudited)

	<u>Jan - Mar 22</u>
OPERATING ACTIVITIES	
Net Income	(6,291.69)
Adjustments to reconcile Net Income	
to net cash provided by operations:	
Prepaid Expenses:Legal & Professional Fees	2,500.00
Prepaid Expenses:OTC Service Fees	2,124.99
Due to Officers	6,603.39
Net cash provided by Operating Activities	<u>4,936.69</u>
Net cash increase for period	4,936.69
Cash at beginning of period	(1,936.69)
Cash at end of period	<u><u>3,000.00</u></u>

The accompanying notes are an integral part of these financial statements.

SOUTHERN HOME MEDICAL INC
Statement of Shareholders' Equity
for the period ended March 31, 2022
(Unaudited)

	Preferred Stock Series A No Par Value		Preferred Stock Series C No Par Value		Common Stock \$0.0001 Par Value		Additional	Accumulated	Total
	Shares	Amount	Shares	Amount	Shares	Amount	Paid-in Capital	(Deficit)	Stockholders' Equity
Balances, January 1, 2022	10,000,000	19,827.00	10,516,250	18,006.00	3,986,704,512	102,907.00		(347,919.20)	(207,179.20)
Net loss for the period								(6,291.69)	(6,291.69)
Balances, March 31, 2022	10,000,000	\$ 19,827.00	10,516,250	\$ 18,006.00	3,986,704,512	\$ 102,907.00		\$ (354,210.89)	\$ (213,470.89)

The accompanying notes are an integral part of these financial statements.

Southern Home Medical, Inc.
March 31, 2022
Notes

Revenues: For three months ended March 31, 2022.

There was no service revenue for the period and for the same period in 2021. The company has launched during the period a new health coach and functional medical platform that provides digital health coach program and clinical functional medical care. Greater revenue is expected to be generated in the near future as the business grows.

Expenses: For three months ended March 31, 2022.

Operating expenses for the period were \$6,292, compared to \$17,291 for the same period in 2021.

Income Taxes: For three months ended March 31, 2022.

The company had no provision for income taxes for the period ended March 31, 2022. We do not currently have any net deferred tax assets.

Impact of Inflation

We believe that inflation has had a negligible effect on operations.

Outstanding Shares:

For three months ended March 31, 2022.

Common	3,986,704,512	There are 1,949 shareholders in common stock
Preferred A	10,000,000	There are 2 shareholders in Preferred A
Preferred C	10,516,250	There 25 shareholders in Preferred C

Authorized Share:

For three months ended March 31, 2022.

Common	5,000,000,000
Preferred A	25,000,000
Preferred C	25,000,000

Liquidity & Capital Resources: For three months ended March 31, 2022.

We do not rely on financing from outside sources to provide us with capital. This has no effect on our operations and financial conditions. Operation will continue as currently configured. However, we have now established strong alliance with our banking partners and feel our position is stronger than ever, in the event we rely on their partnership.

We had a cash balance of \$3,000 on March 31, 2022. Our current amount of cash in the bank is not sufficient for our operations. We will rely on the future revenue from our business to operate and make decisions. Demand for our business will be dependent on, among other things, market acceptance of our potential business in the near future.

Note 1 -- Basic of Presentation

This is preliminary overview unaudited for the period ended March 31, 2022. The accompanying unaudited financial statements are being prepared internally in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they currently do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, the unaudited financial statements contain no current adjustments consisting only of normal recurring accruals considered necessary to present fairly the Company's financial position at March 31, 2022.

Management's Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that effect the reported accounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The carrying amounts of financial instruments including accounts receivables, medical equipment, accounts payables, stockholder loans payable and notes payable approximated fair value of the immediate short-term maturity of these instruments.

Earnings (loss) Per Share

The Company reports earnings (loss) per share in accordance with Statement of Financial Accounting Standards (SFAS) No. 128. This statement requires dual presentation of basic and diluted earnings (loss) with a reconciliation of the numerator and denominator of the loss per share computations. Basic earnings per share amounts are based on the weighted average shares of common outstanding. If applicable, diluted earnings per share assume the conversion, exercise or issuance of all common stock instruments such as options, warrants, and convertible securities, unless the effect is to reduce a loss in increase earnings per share. Accordingly, this presentation has been adopted for the period presented. There were no adjustments required to net income for the period presented in the computation of diluted earnings per share. There were no common stock equivalents (CSE) necessary for the computation of diluted loss per share.

Income Taxes

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of deferred taxes related primarily to differences between the basis of certain assets and liabilities for financial and tax reporting and net operating loss carry-forwards. Deferred taxes present the future tax consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. The income tax benefit consists of taxes currently refundable due to net operating loss carry-back provisions less the effects of accelerated depreciation for the federal tax purposes. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the entire deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effect of changes in tax laws and tax rates on the date of enactment.

Fixed Assets

Fixed assets are recorded at cost and included expenditures that substantially increase the productive lives of the existing assets. Maintenance and repairs costs are expensed as incurred. Depreciation is provided using the straight-line method. Depreciation of property and equipment is calculated over the management prescribed recovery periods, which range from 5 years for equipment to 7 years for furniture and fixtures.

When a fixed asset is disposed of, its cost and related accumulated depreciation are removed from the accounts. The difference between the undepreciated cost and proceeds from disposition is recorded as a gain or loss.

Advertising Costs

Advertising costs are expensed as incurred. The Company did not incur any direct-response advertising costs and nor did the Company employ an agency.

Long-lived Assets

In accordance with Financial Accounting Standards Board Statement of Financial Accounts Standards No. 121, "Accounting for Impairment of Long-lived Assets and for Long-lived Assets to be disposed of," the carrying value of long-lived assets is reviewed by management on a regular basis for the existence of facts or circumstances, both internally and externally, that may suggest impairment. To date, no such impairment has been indicated. Should there be impairment in the future, the Company will recognize the amount of impairment based on discounted expected future cash flows from the impaired assets.

Comprehensive Income (Loss)

The Company adopted Financial Accounting Standards Board Statement of Financial Accounts Standards No. 130, "Reporting Comprehensive Income," which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. There were no items of comprehensive income (loss) applicable to the company during the period covered in the financial statements.

Cash and Cash Equivalents

For purposes of the Statement of Cash Flows, the Company considers liquid investments with an original maturity of nine months or less as cash equivalents.

Other Current Liabilities:

There were \$222,221 loans from officers and/or affiliated companies owned by officers for the period ended March 31, 2022. There are no formal documents evidencing these loans and are payable on demand (which demand has not been made).

Loans Payable

There were no loans made by other parties made to the Company for the period.

Uninsured Deposits

At no times during the period, the Company maintained a bank account balance that exceeded the federal insured limits.

Legal Presentation

There are no legal issues known at present that is a concern for the Company.

Subsequent Events

The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported.

5) Issuer's Business, Products and Services

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Issuer is a thriving health coach and functional medicine platform offering a digital health coach program and in-office medical care for the commercially insured and working population and associated dependents. It strives to make digital health services accessible 24/7 nationwide.

B. Please list any subsidiaries, parents, or affiliated companies.

C. Describe the issuers' principal products or services

The main services we provide are:

1. Providing health coaching services; training and certification for health coaches; offering functional medicine platforms; comprehensive outpatient medical services; and also provide 24/7 remote and digital medical services on a global scale in the near future.

2. In-office medical care with three locations in New York City. Our services include Primary care, Physical Therapy, Chiropractic, Acupuncture, and Occupational Therapy. We anticipate that our headquarters will go live in New Jersey soon, although there are no definitive agreements in place. We are exploring adding a couple of satellite clinics to provide health coach training and in-office visits to those in need. We hope to expand our satellite office network throughout the tri-state area and in other states, but there are no definitive plans.

6) Issuer's Facilities

The Company utilized offices at 6417 18th Ave, Brooklyn, New York 11214.

7) Officers, Directors, and Control Persons

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned*	Share type/class	Ownership Percentage of Class Outstanding	Note
Li Yong	President/Director	6511 Fort Hamilton Brooklyn, NY 11219	2,801,955,000	Common Stock	<u>70%</u>	_____
Li Yong	President/Director	6511 Fort Hamilton, Brooklyn, NY 11219				
Li Yong	President/Director	6511 Fort Hamilton, Brooklyn, NY 11219	6,277,000	Series C Preferred Stock	<u>63%</u>	_____

Jun Wen Tan	Chief Financial Officer/Director	201 Shuhui Rd, Jinsha Ludao Building #2, Ste 201, Qingyang District, Chengdu, Sichuan Province, China	0	-	-	
Lei Yang	Chief Operating Officer	6417 18 th Ave Brooklyn, NY 11204	0	-	-	
Dongmei Chen	Director	176 Jiangjia Lane, Qilin District, Qujing City, Yunan Province, China	0	-	-	

* Information taken from Shareholder List maintained by Transfer Agent for the Company and the State of Wyoming.

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

A. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Jeffrey Stein, Esq.
Firm: JMS Law Group, PLLC
Address 1: 998C Old Country Road, #233, Plainview, NY 11803
Phone: (516) 422-6285
Email: jstein@jmslg.com

Accountant

Name: Vincent Xiao, CPA
Firm: VX Accounting & Tax Inc.
Address 1: 817 60th Street, #2F, Brooklyn, NY 11220
Phone: (718) 872-5666
Email: yx0286138@gmail.com

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Yong Li certify that:

1. I have reviewed this Annual disclosure statement of Southern Home Medical, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/13/2022 [Date]

X [Signature] [CEO's Signature]

Principal Financial Officer:

I, Jun Wen Tan certify that:

1. I have reviewed this Annual disclosure statement of Southern Home Medical, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/16/2022 [Date]

X [Signature] [CFO's Signature]